<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3521">
  <stage>Registered</stage>
  <submitdate>16/04/2012</submitdate>
  <approvaldate>16/04/2012</approvaldate>
  <nctid>NCT01579383</nctid>
  <trial_identification>
    <studytitle>Safety Tolerability and Pharmacokinetics of ALD403</studytitle>
    <scientifictitle>A Single Dose, Placebo-Controlled, Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered by Intravenous Infusion and Subcutaneous Injection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ALD403-CLIN-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Migraine Disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - ALD403
Other interventions - ALD403
Other interventions - Sumatriptan

Experimental: Part A, Cohorts A - H - ALD403/Placebo

Experimental: Part A, Cohort I - ALD403/Placebo

Experimental: Part B - ALD403/Placebo/Sumatriptan


Other interventions: ALD403
Single Dose IV infusion on Day 1

Other interventions: ALD403
Single Dose subcutaneous injection on Day 1

Other interventions: Sumatriptan
Single Dose subcutaneous injection on Day 1

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of ALD403: laboratory variables, ECG and adverse events - Physical Examination
Vital signs
12-lead ECG (electrocardiogram)
Clinical laboratory tests (hematology, chemistry)
Number of participants with Adverse Events</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of Pharmacokinetics of ALD403 - Cmax - maximum plasma concentration
Tmax - Time to achieve maximum plasma concentration
AUC - Area under the plasma concentration-time curve
T1/2 - Elimination half-life
Vz - Volume of distribution
CL - Clearance
Bioavailability</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of pharmacodynamics of ALD403 - Blood perfusion rates
Plasma levels of unbound ALD403
Immunogenicity</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria Part A:

          -  Healthy males and females between the ages of 18 and 65 (inclusive).

          -  Normal renal function as calculated by the Cockcroft- Gault equation at screening.

          -  Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to
             100kg inclusive.

          -  No clinically significant disease or abnormal laboratory values as determined by
             medical history, physical examination, electrocardiogram, and laboratory evaluations</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria Part A:

          -  History of febrile illness within 5 days prior to the first dose

          -  Any clinically significant laboratory findings

          -  Any clinically significant physical exam abnormalities

          -  Hospitalization for any reason within 30 days of the screening visit.

          -  History of or positive human immunodeficiency virus (HIV) screen result

          -  History of positive Hepatitis B surface antigen (HBsAg), and/or positive Hepatitis C
             antibody (HCV) at screening.

          -  History of malignancy within five years prior to screening.

          -  History of leukemia, myeloproliferative disorder or lymphoproliferative disorder

          -  History of rubber, latex allergy or allergy to medical adhesives

          -  Positive urine, drug or alcohol screen result

          -  Current smokers

          -  Previous treatment or clinical trial with a monoclonal antibody.

          -  Participation in any clinical research study evaluating another investigational drug
             or therapy within 30 days or at least 5 half-lives

        Inclusion Criteria Part B:

          -  Healthy females between the ages of 18 and 65 (inclusive).

          -  Male and female migraine patients with clinically diagnosed migraine not attributed to
             another cause with or without aura based on International Headache Society criteria.

          -  Migraine patients must have a history of migraine with or without aura for more than 1
             year with 1-8 moderate or severe migraine attacks per month in the 2 months prior to
             starting in the study.

          -  Normal renal function as defined by Cockcroft- Gault equation at screening.

          -  Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to
             100kg inclusive.

          -  No clinically significant disease or abnormal laboratory values as determined by
             medical history, physical examination, electrocardiogram, and laboratory evaluations
             conducted at the screening visit or at the time of admission

        Exclusion Criteria Part B:

          -  For migraine patients: patient is not able to refrain from use of their usual triptan
             therapy (if applicable) from 48 hours (Day -2) prior to dosing on Day 1 until the
             morning of discharge (Day 3).

          -  Migraine patients who experience migraine with prolonged aura, familiar hemiplegic
             migraine, migrainous infarction or basilar migraine

          -  For migraine patients: patient has more than 8 headache-days per month or has taken
             medication for acute headache on more than 8 days a month in the past 3 months

          -  For migraine patients: patient was greater than 50 years old at the age of migraine
             onset

          -  History of febrile illness within 5 days prior to the first dose

          -  Any clinically significant laboratory findings

          -  Any clinically significant physical exam abnormalities

          -  Previous treatment or clinical trial with a monoclonal antibody.

          -  Hospitalization for any reason within 30 days of the screening visit.

          -  History of or positive human immunodeficiency virus (HIV) screen result

          -  History of positive Hepatitis B surface antigen (HBsAg), and/or positive Hepatitis C
             antibody (HCV

          -  History of malignancy within five years prior to screening.

          -  History of leukemia, myeloproliferative disorder or lymphoproliferative disorder

          -  Positive urine drug or alcohol screen result

          -  Current smokers.

          -  Known contraindication to sumatriptan

          -  Participation in any clinical research study evaluating another investigational drug
             or therapy within 30 days or at least 5 half-lives</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>104</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Centre for Clinical Studies, Nucleus Network - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alder Biopharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
      ALD403, a monoclonal antibody, administered by intravenous infusion and subcutaneous
      injection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01579383</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Hodsman, MD</name>
      <address>Nucleus Network</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>